688 related articles for article (PubMed ID: 26254083)
21. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
24. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
25. [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases].
Miheller P; Tóth M; Molnár E; Zágoni T; Rácz K; Tulassay Z
Orv Hetil; 2001 Jul; 142(29):1557-60. PubMed ID: 11494747
[TBL] [Abstract][Full Text] [Related]
26. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
28. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
29. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
Maeno Y; Inaba M; Okuno S; Yamakawa T; Ishimura E; Nishizawa Y
Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
[TBL] [Abstract][Full Text] [Related]
30. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease.
Heijckmann AC; Huijberts MS; Schoon EJ; Geusens P; de Vries J; Menheere PP; van der Veer E; Wolffenbuttel BH; Stockbrugger RW; Dumitrescu B; Nieuwenhuijzen Kruseman AC
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):740-7. PubMed ID: 18617778
[TBL] [Abstract][Full Text] [Related]
33. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
34. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease.
Paganelli M; Albanese C; Borrelli O; Civitelli F; Canitano N; Viola F; Passariello R; Cucchiara S
Inflamm Bowel Dis; 2007 Apr; 13(4):416-23. PubMed ID: 17206686
[TBL] [Abstract][Full Text] [Related]
35. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
Miheller P; Muzes G; Zagoni T; Toth M; Racz K; Tulassay Z
Dig Dis; 2006; 24(1-2):201-6. PubMed ID: 16699279
[TBL] [Abstract][Full Text] [Related]
36. Bone density and bone metabolism in patients with inflammatory bowel disease.
Shirazi KM; Somi MH; Rezaeifar P; Fattahi I; Khoshbaten M; Ahmadzadeh M
Saudi J Gastroenterol; 2012; 18(4):241-7. PubMed ID: 22824766
[TBL] [Abstract][Full Text] [Related]
37. Bone mineral density and inflammatory bowel disease severity.
Lima CA; Lyra AC; Mendes CMC; Lopes MB; Coqueiro FG; Rocha R; Santana GO
Braz J Med Biol Res; 2017 Oct; 50(12):e6374. PubMed ID: 29069227
[TBL] [Abstract][Full Text] [Related]
38. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption.
Aonuma H; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
Tohoku J Exp Med; 2009 Jul; 218(3):201-5. PubMed ID: 19561390
[TBL] [Abstract][Full Text] [Related]
39. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
Miheller P; Muzes G; Rácz K; Blázovits A; Lakatos P; Herszényi L; Tulassay Z
Inflamm Bowel Dis; 2007 Nov; 13(11):1379-84. PubMed ID: 17663430
[TBL] [Abstract][Full Text] [Related]
40. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease.
Sylvester FA; Wyzga N; Hyams JS; Davis PM; Lerer T; Vance K; Hawker G; Griffiths AM
Inflamm Bowel Dis; 2007 Jan; 13(1):42-50. PubMed ID: 17206638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
